US Stock MarketDetailed Quotes
ONCY Oncolytics Biotech
- 1.038
- +0.018+1.75%
Trading Jul 12 13:39 ET
78.73MMarket Cap-3542P/E (TTM)
1.040High1.020Low120.40KVolume1.020Open1.020Pre Close124.06KTurnover0.17%Turnover RatioLossP/E (Static)75.85MShares3.08052wk High4.68P/B75.37MFloat Cap0.88352wk Low--Dividend TTM72.62MShs Float7.400Historical High--Div YieldTTM1.96%Amplitude0.351Historical Low1.030Avg Price1Lot Size
Oncolytics Biotech Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -21.81%-28.45M | -3.12%-6.12M | -41.98%-6.03M | -22.38%-8.47M | -25.22%-7.83M | -4.11%-23.36M | 6.25%-5.94M | -13.77%-4.25M | -1.77%-6.92M | -12.28%-6.25M |
| Net income from continuing operations | -11.75%-27.75M | 53.83%-3.95M | -125.16%-9.93M | -46.05%-7.44M | 5.04%-6.44M | 5.58%-24.84M | -10.36%-8.55M | 9.53%-4.41M | 29.69%-5.09M | -5.35%-6.78M |
| Operating gains losses | -211.71%-5M | -6,943.28%-4.59M | 44.33%-707K | 153.87%444K | -136.64%-155K | -492.42%-1.61M | -77.42%67K | -5.36%-1.27M | -230.07%-824.14K | -38.17%423K |
| Depreciation and amortization | 2.81%403K | 8.08%107K | 6.19%103K | -1.65%96K | -1.02%97K | -13.27%392K | 2.16%99K | 14.76%97K | -40.42%97.61K | -8.18%98K |
| Other non cash items | 193.42%71K | 112.86%18K | 289.47%74K | 251.67%75K | -500.00%-96K | -182.61%-76K | -635.33%-140K | -31.13%19K | -12.77%21.33K | 73.80%24K |
| Change In working capital | 351.41%1.77M | -17.07%1.53M | 350.92%3.68M | -17.03%-1.88M | -136.68%-1.56M | 143.06%391K | 1,492.02%1.84M | -33.50%815K | -14.41%-1.61M | -10.15%-657K |
| -Change in receivables | 46.67%506K | 2,662.50%615K | ---71K | 167.49%171K | -127.36%-209K | 144.46%345K | 96.09%-24K | ---- | -947.41%-253.39K | 3,572.10%764K |
| -Change in prepaid assets | 162.31%777K | 11.78%1.48M | --1.59M | -57.48%-2.22M | 94.47%-65K | -257.31%-1.25M | 176.77%1.32M | ---- | 12.93%-1.41M | -158.51%-1.18M |
| -Change in payables and accrued expense | -104.69%-78K | -393.01%-964K | --2.17M | -0.63%133K | -2,424.59%-1.42M | 808.20%1.66M | 195.02%329K | ---- | -51.39%133.85K | -46.31%61K |
| -Change in other current liabilities | 194.32%332K | --239K | --93K | --0 | --0 | -254.39%-352K | --0 | ---- | --0 | -183.91%-352K |
| -Change in other working capital | 1,441.18%228K | -26.07%156K | ---104K | 151.66%39K | 204.44%137K | 91.24%-17K | 10,881.81%211K | ---- | -122.20%-75.5K | 141.06%45K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -21.81%-28.45M | -3.12%-6.12M | -41.98%-6.03M | -22.38%-8.47M | -25.22%-7.83M | -4.11%-23.36M | 6.25%-5.94M | -13.77%-4.25M | -1.77%-6.92M | -12.28%-6.25M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 199.11%20.22M | 99.99%-3K | 75,277.78%6.77M | 58,408.29%6.79M | 18,625.00%6.67M | -7,033.92%-20.4M | -27,114.97%-20.35M | 95.60%-9K | -76.49%-11.65K | -36K |
| Net PPE purchase and sale | 85.45%-8K | -400.00%-3K | --0 | --0 | 86.11%-5K | 80.77%-55K | 101.34%1K | 95.60%-9K | -76.49%-11.65K | ---36K |
| Net investment purchase and sale | 199.42%20.23M | --0 | --6.77M | --6.79M | --6.67M | ---20.35M | ---20.35M | --0 | ---- | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 199.11%20.22M | 99.99%-3K | 75,277.78%6.77M | 58,408.29%6.79M | 18,625.00%6.67M | -7,033.92%-20.4M | -27,114.97%-20.35M | 95.60%-9K | -76.49%-11.65K | ---36K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 162.14%31.99M | -70.32%1.74M | 1,727.38%21.29M | 2,262.59%3.69M | 5.13%5.27M | -63.03%12.21M | 11,305.07%5.87M | 1,562.28%1.17M | -98.04%156.27K | -80.08%5.01M |
| Net issuance payments of debt | -6.82%-407K | -1.96%-104K | -6.25%-102K | -6.76%-100K | -13.48%-101K | -4.10%-381K | -26.71%-102K | -27.53%-96K | 4.96%-93.67K | 20.30%-89K |
| Net common stock issuance | 151.47%31.62M | -75.37%1.47M | 1,591.36%21.33M | 1,279.95%3.45M | 5.52%5.37M | -61.80%12.57M | 66,507.21%5.97M | 13,761.97%1.26M | -96.90%249.94K | -79.52%5.09M |
| Proceeds from stock option exercised by employees | 6,408.33%781K | --375K | --63K | ---- | ---- | -97.44%12K | --0 | --0 | --0 | -97.14%12K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 162.14%31.99M | -70.32%1.74M | 1,727.38%21.29M | 2,262.59%3.69M | 5.13%5.27M | -63.03%12.21M | 11,305.07%5.87M | 1,562.28%1.17M | -98.04%156.27K | -80.08%5.01M |
| Net cash flow | ||||||||||
| Beginning cash position | -71.73%11.67M | 23.54%39.98M | -47.99%17.52M | -59.80%15.87M | -71.73%11.67M | 32.17%41.26M | -32.70%32.36M | -33.68%33.69M | -21.60%39.48M | 32.17%41.26M |
| Current changes in cash | 175.33%23.77M | 78.52%-4.39M | 812.55%22.03M | 129.78%2.02M | 422.68%4.11M | -406.46%-31.55M | -215.95%-20.42M | 23.06%-3.09M | -675.27%-6.77M | -106.50%-1.27M |
| Effect of exchange rate changes | -126.67%-522K | -144.29%-684K | -75.28%436K | -137.70%-369K | 118.81%95K | 870.47%1.96M | 23.07%-280K | 35.15%1.76M | 232.27%978.82K | -10.93%-505K |
| End cash Position | 199.26%34.91M | 199.26%34.91M | 23.54%39.98M | -48.00%17.52M | -59.80%15.87M | -71.73%11.67M | -71.73%11.67M | -32.70%32.36M | -33.68%33.69M | -21.60%39.48M |
| Free cash flow | -21.55%-28.46M | -3.18%-6.13M | -41.68%-6.03M | -22.17%-8.47M | -24.59%-7.83M | -3.04%-23.41M | 7.36%-5.94M | -8.09%-4.26M | -1.84%-6.93M | -12.92%-6.29M |
| Currency Unit | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg